1.The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study.
Jae Ho BYUN ; Joong Bae AHN ; Sun Young KIM ; Jung Hun KANG ; Dae Young ZANG ; Seok Yun KANG ; Myoung Joo KANG ; Byoung Yong SHIM ; Sun Kyung BAEK ; Bong Seog KIM ; Kyung Hee LEE ; Soon Il LEE ; Sang Hee CHO ; Byeong Seok SOHN ; Samyong KIM ; In Gyu HWANG ; Eun Mi NAM ; Bong Gun SEO ; Sang Cheul OH ; Myung Ah LEE ; Sang Cheol LEE ; Ji Hyung HONG ; Young Suk PARK
The Korean Journal of Internal Medicine 2019;34(1):165-177
BACKGROUND/AIMS: Colorectal cancer is associated with different anatomical, biological, and clinical characteristics. We determined the impact of the primary tumor location in patients with metastatic colorectal cancer (mCRC). METHODS: Demographic data and clinical information were collected from 1,115 patients from the Republic of Korea, who presented with mCRC between January 2009 and December 2011, using web-based electronic case report forms. Associations between the primary tumor location and the patient's clinical characteristics were assessed, and factors inf luencing overall survival were analyzed using Cox proportional hazards regression models. RESULTS: Of the 1,115 patients recruited to the study, 244 (21.9%) had right colon cancer, 483 (43.3%) had left colon cancer, and 388 (34.8%) had rectal cancer. Liver and lung metastases occurred more frequently in patients with left colon and rectal cancer (p = 0.005 and p = 0.006, respectively), while peritoneal and ovarian metastases occurred more frequently in patients with right and left colon cancer (p < 0.001 and p = 0.031, respectively). The median overall survival of patients with tumors originating in the right colon was significantly shorter than that of patients whose tumors had originated in the left colon or rectum (13.7 months [95% confidence interval (CI), 12.0 to 15.5] vs. 18.0 months [95% CI, 16.3 to 19.7] or 19.9 months [95% CI, 18.5 to 21.3], respectively; p = 0.003). Tumor resection, the number of metastatic sites, and primary tumor location correlated with overall survival in the univariate and multivariate analyses. CONCLUSIONS: Primary tumor location influences the metastatic sites and prognosis of patients with mCRC.
Colon
;
Colonic Neoplasms
;
Colorectal Neoplasms*
;
Humans
;
Liver
;
Lung
;
Multivariate Analysis
;
Neoplasm Metastasis
;
Prognosis
;
Rectal Neoplasms
;
Rectum
;
Republic of Korea
2.Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study).
Dae Won JUN ; Sang Bong AHN ; Tae Yeob KIM ; Joo Hyun SOHN ; Sang Gyune KIM ; Se Whan LEE ; Byung Ho KIM ; Dong Joon KIM ; Ja Kyung KIM ; Hyoung Su KIM ; Seong Gyu HWANG ; Won Choong CHOI ; Won Young TAK ; Heon Ju LEE ; Ki Tae YOON ; Byung Cheol YUN ; Sung Wook LEE ; Soon Koo BAIK ; Seung Ha PARK ; Ji Won PARK ; Sol Ji PARK ; Ji Sung LEE
Chinese Medical Journal 2018;131(14):1645-1651
BackgroundUntil now, various types of combined therapy with nucleotide analogs and pegylated interferon (Peg-INF) in patients with hepatitis B patients have been tried. However, studies regarding the benefits of de novo combination, late-add on, and sequential treatment are very limited. The objective of the current study was to identify the efficacy of sequential treatment of Peg-INF after short-term antiviral treatment.
MethodsBetween June 2010 and June 2015, hepatitis B e antigen (HBeAg)-positive patients (n = 162) received Peg-IFN for 48 weeks (mono-treatment group, n = 81) and entecavir (ETV) for 12 weeks with a 48-week course of Peg-IFN starting at week 5 of ETV therapy (sequential treatment group, n = 81). The primary endpoint was HBeAg seroconversion at the end of follow-up period after the 24-week treatment. The primary endpoint was analyzed using Chi-square test, Fisher's exact test, and regression analysis.
ResultsHBeAg seroconversion rate (18.2% vs. 18.2%, t = 0.03, P = 1.000) and seroclearance rate (19.7% vs. 19.7%, t = 0.03, P = 1.000) were same in both mono-treatment and sequential treatment groups. The rate of alanine aminotransferase (ALT) normalization (45.5% vs. 54.5%, t = 1.12, P = 0.296) and serum hepatitis B virus (HBV)-DNA <2000 U/L (28.8% vs. 28.8%, t = 0.10, P = 1.000) was not different in sequential and mono-treatment groups at 24 weeks of Peg-INF. Viral response rate (HBeAg seroconversion and serum HBV-DNA <2000 U/L) was not different in the two groups (12.1% vs. 16.7%, t = 1.83, P = 0.457). Baseline HBV-DNA level (7 logU/ml vs. 7.5 logU/ml, t = 1.70, P = 0.019) and hepatitis B surface antigen titer (3.6 logU/ml vs. 4.0 logU/ml, t = 2.19, P = 0.020) were lower and predictors of responder in mono-treatment and sequential treatment groups, respectively.
ConclusionsThe current study shows no differences in HBeAg seroconversion rate, ALT normalization, and HBV-DNA levels between mono-therapy and sequential therapy regimens.
Trial RegistrationClinicalTrials.gov, NCT01220596; https://clinicaltrials.gov/ct2/show/NCT01220596?term=NCT01220596&rank=1.
3.Neuraminidase Inhibitors from the Fruiting Body of Phellinus igniarius.
Ji Yul KIM ; Dae Won KIM ; Byung Soon HWANG ; E Eum WOO ; Yoon Ju LEE ; Kyeong Woon JEONG ; In Kyoung LEE ; Bong Sik YUN
Mycobiology 2016;44(2):117-120
During our ongoing investigation of neuraminidase inhibitors from medicinal fungi, we found that the fruiting bodies of Phellinus igniarius exhibited significant inhibitory activity against neuraminidase from recombinant H3N2 influenza viruses. Two active compounds were isolated from the methanolic extract of P. igniarius through solvent partitioning and Sephadex LH-20 column chromatography. The active compounds were identified as phelligridins E and G on proton nuclear magnetic resonance (¹H NMR) and electrospray ionization mass measurements. These compounds inhibited neuraminidases from recombinant rvH1N1, H3N2, and H5N1 influenza viruses, with IC₅₀ values in the range of 0.7~8.1 µM.
Chromatography
;
Fruit*
;
Fungi
;
Magnetic Resonance Spectroscopy
;
Methanol
;
Neuraminidase*
;
Orthomyxoviridae
;
Protons
4.Antifungal Substances from Streptomyces sp. A3265 Antagonistic to Plant Pathogenic Fungi.
Nguyen VAN MINH ; E Eum WOO ; Ji Yul KIM ; Dae Won KIM ; Byung Soon HWANG ; Yoon Ju LEE ; In Kyoung LEE ; Bong Sik YUN
Mycobiology 2015;43(3):333-338
In a previous study, we identified a Streptomyces sp., A3265, as exhibiting potent antifungal activity against various plant pathogenic fungi, including Botrytis cinerea, Colletotrichum gloeosporioides, and Rhizoctonia solani. This strain also exhibited a biocontrolling effect against ginseng root rot and damping-off disease, common diseases of ginseng and other crops. In this study, we isolated two antifungal substances responsible for this biocontrolling effect via Diaion HP-20 and Sephadex LH-20 column chromatography, medium pressure liquid chromatography, and high-performance liquid chromatography. These compounds were identified as guanidylfungin A and methyl guanidylfungin A by spectroscopic methods. These compounds exhibited potent antimicrobial activity against various plant pathogenic fungi as well as against bacteria.
Bacteria
;
Botrytis
;
Chromatography
;
Chromatography, Liquid
;
Colletotrichum
;
Fungi*
;
Panax
;
Plants*
;
Rhizoctonia
;
Streptomyces*
5.Chemical Constituents of the Culture Broth of Phellinus linteus and Their Antioxidant Activity.
Myeong Seok LEE ; Byung Soon HWANG ; In Kyoung LEE ; Geon Sik SEO ; Bong Sik YUN
Mycobiology 2015;43(1):43-48
The medicinal fungus Phellinus linteus, in the family Hymenochaetaceae, has been used as a traditional medicine for the treatment of various diseases. In this study, the chemical constituents of the culture broth of P. linteus were investigated. P. linteus was cultured in potato dextrose broth medium, and the culture broth was extracted with ethyl acetate. The ethyl acetate-soluble portion was concentrated and subjected to ODS column chromatography, followed by Sephadex LH-20 column chromatography. Six compounds (1~6) were purified by preparative reversed-phase high-performance liquid chromatography. Spectroscopic methods identified their structures as caffeic acid (1), inotilone (2), 4-(3,4-dihydroxyphenyl)-3-buten-2-one (3), phellilane H (4), (2E,4E)-(+)-4'-hydroxy-gamma-ionylideneacetic acid (5), and (2E,4E)-gamma-ionylideneacetic acid (6). Compounds 1, 2, and 3 exhibited potent dose-dependent antioxidant activity.
Chromatography
;
Chromatography, Liquid
;
Fungi
;
Glucose
;
Humans
;
Medicine, Traditional
;
Solanum tuberosum
6.Neuraminidase Inhibitors from the Fermentation Broth of Phellinus linteus.
Byung Soon HWANG ; Myeong Seok LEE ; Seung Woong LEE ; In Kyoung LEE ; Geon Sik SEO ; Hwa Jung CHOI ; Bong Sik YUN
Mycobiology 2014;42(2):189-192
During a search for neuraminidase inhibitors derived from medicinal fungi, we found that the fermentation broth of Phellinus linteus exhibited potent neuraminidase inhibitory activity. Through bioassay-guided fractionation, two active compounds were purified from the ethyl acetate-soluble portion of the fermentation broth of P. linteus. These structures were identified as inotilone (1) and 4-(3,4-dihydroxyphenyl)-3-buten-2-one (2) by spectroscopic methods. Compounds 1 and 2 inhibited H1N1 neuraminidase activity with IC50 values of 29.1 and 125.6 microM, respectively, in a dose-dependent manner. They also exhibited an antiviral effect in a viral cytopathic effect reduction assay using MDCK cells. These results suggest that compounds 1 and 2 from the culture broth of P. linteus would be good candidates for the prevention and therapeutic strategies towards viral infections.
Cytopathogenic Effect, Viral
;
Fermentation*
;
Fungi
;
Inhibitory Concentration 50
;
Madin Darby Canine Kidney Cells
;
Neuraminidase*
7.Lipoxygenase Inhibitory Activity of Korean Indigenous Mushroom Extracts and Isolation of an Active Compound from Phellinus baumii.
Seung Woong LEE ; Ja Gyeong SONG ; Byung Soon HWANG ; Dae Won KIM ; Yoon Ju LEE ; E Eum WOO ; Ji Yul KIM ; In Kyoung LEE ; Bong Sik YUN
Mycobiology 2014;42(2):185-188
We investigated a total of 335 samples of Korean native mushroom extracts as part of our lipoxygenase (LOX) inhibitor screening program. Among the mushroom-methanolic extracts we investigated, 35 exhibited an inhibitory activity greater than 30% against LOX at a concentration of 100 microg/mL. Especially, Collybia maculata, Tylopilus neofelleus, Strobilomyces confusus, Phellinus gilvus, P. linteus, P. baumii, and Inonotus mikadoi exhibited relatively potent LOX inhibitory activities of 73.3%, 51.6%, 52.4%, 66.7%, 59.5%, 100.0%, and 85.2%, respectively. Bioassay-guided fractionation led to the isolation of inoscavin A from the methanolic extract of P. baumii, which showed the most potent activity and was identified by spectroscopic methods. Specifically, inoscavin A exhibited potent LOX inhibitory activity with an IC50 value of 6.8 microM.
Agaricales*
;
Inhibitory Concentration 50
;
Lipoxygenase*
;
Mass Screening
;
Methanol
8.New Bioactive Compounds from Korean Native Mushrooms.
Seong Eun KIM ; Byung Soon HWANG ; Ja Gyeong SONG ; Seung Woong LEE ; In Kyoung LEE ; Bong Sik YUN
Mycobiology 2013;41(4):171-176
Mushrooms are ubiquitous in nature and have high nutritional attributes. They have demonstrated diverse biological effects and therefore have been used in treatments of various diseases, including cancer, diabetes, bacterial and viral infections, and ulcer. In particular, polysaccharides, including beta-glucan, are considered as the major constituents responsible for the biological activity of mushrooms. Although an overwhelming number of reports have been published on the importance of polysaccharides as immunomodulating agents, not all of the healing properties found in these mushrooms could be fully accounted for. Recently, many research groups have begun investigations on biologically active small-molecular weight compounds in wild mushrooms. In this mini-review, both structural diversity and biological activities of novel bioactive substances from Korean native mushrooms are described.
Agaricales*
;
Polysaccharides
;
Ulcer
9.Taurine ameliorates hyperglycemia and dyslipidemia by reducing insulin resistance and leptin level in Otsuka Long-Evans Tokushima fatty (OLETF) rats with long-term diabetes.
Kyoung Soo KIM ; Da Hee OH ; Jung Yeon KIM ; Bong Gn LEE ; Jeong Soon YOU ; Kyung Ja CHANG ; Hyunju CHUNG ; Myung Chul YOO ; Hyung In YANG ; Ja Heon KANG ; Yoo Chul HWANG ; Kue Jeong AHN ; Ho Yeon CHUNG ; In Kyung JEONG
Experimental & Molecular Medicine 2012;44(11):665-673
This study aimed to determine whether taurine supplementation improves metabolic disturbances and diabetic complications in an animal model for type 2 diabetes. We investigated whether taurine has therapeutic effects on glucose metabolism, lipid metabolism, and diabetic complications in Otsuka Long-Evans Tokushima fatty (OLETF) rats with long-term duration of diabetes. Fourteen 50-week-old OLETF rats with chronic diabetes were fed a diet supplemented with taurine (2%) or a non-supplemented control diet for 12 weeks. Taurine reduced blood glucose levels over 12 weeks, and improved OGTT outcomes at 6 weeks after taurine supplementation, in OLETF rats. Taurine significantly reduced insulin resistance but did not improve beta-cell function or islet mass. After 12 weeks, taurine significantly decreased serum levels of lipids such as triglyceride, cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol. Taurine significantly reduced serum leptin, but not adiponectin levels. However, taurine had no therapeutic effect on damaged tissues. Taurine ameliorated hyperglycemia and dyslipidemia, at least in part, by improving insulin sensitivity and leptin modulation in OLETF rats with long-term diabetes. Additional study is needed to investigate whether taurine has the same beneficial effects in human diabetic patients.
Adipokines/blood
;
Animals
;
Blood Glucose
;
Diabetes Mellitus, Type 2/drug therapy
;
Dietary Supplements
;
Dyslipidemias/blood/*drug therapy
;
Glucose Tolerance Test
;
Hyperglycemia/blood/*drug therapy
;
Hypoglycemic Agents/administration & dosage/*pharmacology
;
Hypolipidemic Agents/administration & dosage/*pharmacology
;
Insulin/physiology/secretion
;
Insulin Resistance
;
Insulin-Secreting Cells/physiology/secretion
;
Leptin/*blood
;
Lipid Metabolism/drug effects
;
Lipids/blood
;
Male
;
Organ Specificity
;
Rats
;
Rats, Long-Evans
;
Taurine/administration & dosage/*pharmacology
10.The Effect of High Frequency Repetitive Transcranial Magnetic Stimulation on the Motor Function in Post-Stroke Patients.
Min Kyun SOHN ; Bong Ok KIM ; Sung Gyum KIM ; Pil Soon CHOI ; Sun Hong HWANG
Journal of the Korean Academy of Rehabilitation Medicine 2010;34(2):168-173
OBJECTIVE: To evaluate the effects of high frequency repetitive transcranial magnetic stimulation (rTMS) of the affected hemisphere on the motor recovery and spasticity in chronic post-stroke hemiplegic patients. METHOD: Thirteen chronic stroke hemiplegic patients were randomized to receive real and sham rTMS. rTMS was carried out 10 times at a frequency of 10 Hz with 10 s stimulation followed by 50 s rest, totalling 1,000 stimulations to the affected primary motor cortex using an intensity of 100% of resting motor threshold of unaffected hemisphere. Median nerve H-reflex, modified Ashworth scale (MAS) at elbow and wrist, and manual function test (MFT) were measured at baseline and after 2 weeks of treatment. RESULTS: High frequency rTMS resulted in increased H-reflex latency and decreased H-reflex amplitude and H/M ratio. Also MAS decreased and MFT score increased after 2 weeks of treatment. CONCLUSION: High frequency rTMS in the affected motor cortex might facilitate motor recovery and reduce spasticity in chronic stroke patients.
Elbow
;
H-Reflex
;
Humans
;
Median Nerve
;
Motor Cortex
;
Muscle Spasticity
;
Salicylamides
;
Stroke
;
Transcranial Magnetic Stimulation
;
Wrist

Result Analysis
Print
Save
E-mail